Dr. John Trachtenberg received his B.Sc., M.D. and C.M. from McGill University in Montreal. He completed his urologic residency at McGill University and succeeded to a fellowship in prostatic disease at Johns Hopkins University. Dr. Trachtenberg is currently Professor of Surgery and Medical Imaging at the University of Toronto. He holds the prestigious Fleck Tanenbaum Chair in Prostatic Diseases at the University of Toronto and University Health Network. He is the Director of the Prostate Centre at the Princess Margaret Hospital of the University Health Network. He acts as a consultant to the Urology Department at numerous hospitals. Dr. Trachtenberg has published over 225 peer reviewed scientific papers and several books, and sits on many hospital, university and scientific committees throughout North America and Europe. His accomplishments have earned him 18 awards, including Man of the Year in Sciences and Medicine from the Canadian Prostate Cancer Research Fund. He has developed novel, minimally invasive surgical techniques for the treatment of prostate cancer and was instrumental in the development of the prostate-specific Clinical Research Program at Princess Margaret Hospital.
Dr. Trachtenberg's major interests include the investigation of novel treatments for localized and advanced prostate cancer, developing minimally invasive image guided treatments for prostate cancer and the measurement and preservation of the quality of life of men with prostate cancer.
Influence of physical activity on active surveillance discontinuation in men with low-risk prostate cancer.
Cancer Causes Control. 2019 Jul 15;:
Nat Rev Urol. 2019 Apr 05;:
Pfilates and Hypopressives for the Treatment of Urinary Incontinence after Radical Prostatectomy: Results of a Feasibility Randomized Controlled Trial.
PM R. 2019 Mar 14;:
The Prostate Cancer Rehabilitation Clinic: a biopsychosocial clinic for sexual dysfunction after radical prostatectomy.
Curr Oncol. 2018 Dec;25(6):393-402
Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial.
Eur Radiol. 2018 Apr 25;:
Can Urol Assoc J. 2017 Dec 01;:
Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors.
Oncol Lett. 2017 Jul;14(1):390-396
Psychological distress and lifestyle disruption in low risk prostate cancer patients: Comparison between active surveillance and radical prostatectomy.
J Psychosoc Oncol. 2017 Jun 14;:0
J Natl Cancer Inst. 2017 Apr 01;109(4):
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Director, The Prostate Centre, University Health Network
Professor of Surgery and Medical Imaging, University of Toronto